Skip to content
DataLookout
Menu

NCT07793240

Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Oct 1, 2026 to Dec 1, 2026
    • Eligibility criteria expanded, about 2 words
    • Primary completion pushed from Oct 1, 2028 to Dec 1, 2028
    • Study completion pushed from Oct 1, 2029 to Dec 1, 2029
  2. Notable Eligibility criteria expanded, about 27 wordsv2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percent of of tumor informed ctDNA test results on Signatera platform available
Timeframe: until end of surveillance or adjuvant therapy, approximately 5 years
Correlation between perioperative ctDNA dynamics in UTUC with pathologic and clinical outcomes in patients with UTUC who proceed to surgery or renal preservation following induction therapy and or surgery
Timeframe: Up to approximately 5 years
Number of patients with ctDNA decline to zero and radiographic complete response after treatment
Timeframe: until end of surveillance or adjuvant therapy, approximately 5 years

Arms and interventions

High Grade (HG) Upper Tract Urothelial Cancer (UTUC)

Patients HG UTUC planned for systemic therapy and or surgical intervention will be recruited and have sequential ctDNA ordered as per standard Signatera testing (approved for patients with high risk urothelial cancer undergoing immunotherapy or in perioperative setting) at or close to baseline, every 4-6 weeks on treatment, before and after surgical intervention, on surveillance and or adjuvant therapy.

Diagnostic tests: Signatera testing

Sites

1 site in 1 country

  • Johns Hopkins University: Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland, United States